Abstract PD18-03: Final analysis of the Phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Zhi-Ming Shao, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yong-Sheng Wang, Chuan Wang, Yuan-Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Liang Huang, Haiyan Wang, François Lamour, Grace Song, Eleonora Restuccia
Institutions: Fudan University, Fudan University Shanghai Cancer Center, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, University of Chinese Academy of Sciences, First Hospital of Jilin University, Sun Yat-sen University Cancer Center, Zhengzhou University, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Shandong Tumor Hospital, Mackay Memorial Hospital, Roche (China), Ajou University, Korea University Guro Hospital, Shanghai Jiao Tong University, Ruijin Hospital, Prince of Songkla University, 307th Hospital of Chinese People’s Liberation Army, F. Hoffmann-La Roche AG, Hangzhou Tigermed Consulting Co., Ltd. (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4322769402